Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antioxidants and Pentoxifylline for Severe COVID-19 Pneumonia
NCT04570254Completed
- Sponsor
- Unidad Temporal COVID-19 Centro Citibanamex
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of pentoxifylline in COVID-19 pneumonia (2 arms), sponsored by Unidad Temporal COVID-19 Centro Citibanamex. Primary endpoints: Death from any cause at 30 days, Percentage of patients who required orotracheal intubation at 1 week and 2 more. Started Aug 2020; status: completed.
02
Drugs
pentoxifylline
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04570254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570254.